You are here: Industry Insights > viral vector

News List

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX Production Platform PharmaSources
May 05, 2023
May 04, 2023，ProBioGen announces that their proprietary vaccine production cell line AGE1.CR.pIX has been successfully used to manufacture a viral vector product that has advanced into a randomized phase II clinical trial.
GMP certification for Exothera further extends its viral vector manufacturing capacity PharmaSources.com
March 24, 2022
Exothera S.A., a CDMO specialized in the development and manufacture of viral vectors for vaccines and gene therapies, received Good Manufacturing Practices (GMP) certification from the Federal Agency for Medicines and Health Products...
Successful Groundbreaking Ceremony for GenScript ProBio to Expand Commercial cGMP Plasmid and Viral Vector Manufacturing Facility in Zhenjiang, China prnasia
January 21, 2022
GenScript ProBio, a global antibody and gene therapy contract development and manufacturing organization (CDMO), has announced 2022 manufacturing expansion plans to meet the increasing demand for commercial cGMP...
Carina Biotech, CellVec Enter Clinical Mfg. Pact for Cell Therapy ContractPharma
November 10, 2021
CellVec, a Singapore-based viral vector CDMO, has been selected as the manufacturer of choice for Australian cell therapy immuno-oncology company Carina Biotech...
Viral vector demand to flourish on wave of imminent approvals, CPhI Worldwide audience told CPhIonline
November 03, 2021
In the live session, Building Viral Vector Capacity and Capabilities to Realise the Promise of Gene Therapies sponsored by Thermo Fisher Scientific, experts discussed how continuing advances...
Catalent embarks on $230M viral vector expansion project at Harmans campus CPhIonline
October 28, 2021
CDMO Catalent is to spend $230 million on adding three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene therapy campus in Harmans, Maryland.
Matica Bio and Sartorius form large-scale vector production research pact CPhIonline
October 21, 2021
Matica Biotechnology and Sartorius have struck a joint research agreement to streamline and optimise process analytical technologies, automation software, and single-use platforms offered by Sartorius for large-scale viral vector production.
First UK-based clinical trial focused viral vector manufacturer announces launch pharmatimes
April 30, 2021
ViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.
Could viral vector shortages disrupt the COVID-19 vaccine roll-out? europeanpharmaceuticalreview
March 26, 2021
According to GlobalData, AstraZeneca’s and Janssen’s COVID-19 vaccines could be impacted by global viral vector shortages.
Emergent BioSolutions Enters Viral Vector and Gene Therapy Arena contractpharma
June 19, 2020
Invests $75mn in Canton site, advanced therapy CDMO drug substance manufacturing services expected to be available beginning in 2023.

Previous page 1 2 Next page